Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for cutaneous T-cell lymphomas; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications and tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. It also provides IPH5201, an anti-CD39 antibody and IPH5301, an anti-CD73 antibody, which is in pre-clinical stage for the treatment of immuno-oncology. In addition, the company offers IPH61, a bispecific NK cell engager that is used to create novel molecular formats to kill tumor cells through NKp46. Further, it provides Lumoxiti, a commercial-stage oncology product for treating hairy cell leukemia. Innate Pharma S.A. has licensing agreements with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi; and a clinical trial collaboration with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone33-4-30-30-30-30
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees200
Next Earnings DateN/A
OptionableNot Optionable
Innate Pharma (NASDAQ:IPHA) Frequently Asked Questions
What is Innate Pharma's stock symbol?
Innate Pharma trades on the NASDAQ under the ticker symbol "IPHA."
Has Innate Pharma been receiving favorable news coverage?
News coverage about IPHA stock has trended very negative on Monday, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Innate Pharma earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Innate Pharma.
Who are some of Innate Pharma's key competitors?
Some companies that are related to Innate Pharma include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), Moderna (MRNA), argenx (ARGX), China Biologic Products (CBPO), bluebird bio (BLUE), Spark Therapeutics (ONCE), Repligen (RGEN) and BioNTech (BNTX).
Who are Innate Pharma's key executives?
Innate Pharma's management team includes the folowing people:
- Dr. Hervé Brailly, Co-Founder & Chairman of Supervisory Board (Age 58)
- Dr. Mondher Mahjoubi, Chairman of Exec. Board & CEO (Age 61)
- Mr. Yannis Morel, Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board (Age 46)
- Ms. Laure-Hélène Mercier M.B.A., M.Sc., MSc, MBA, Exec. VP, CFO & Member of Exec. Board (Age 41)
- Mr. Eric Vivier D.V.M., Ph.D., Sr. VP & Chief Scientific Officer (Age 55)
When did Innate Pharma IPO?
(IPHA) raised $80 million in an IPO on Thursday, October 17th 2019. The company issued 10,700,000 shares at $7.50 per share. Citigroup, SVB Leerink and Evercore ISI served as the underwriters for the IPO.
When does Innate Pharma's quiet period expire?
Innate Pharma's quiet period expires on Tuesday, November 26th. Innate Pharma had issued 12,500,000 shares in its initial public offering on October 17th. The total size of the offering was $68,750,000 based on an initial share price of $5.50. During Innate Pharma's quiet period, insiders and underwriters involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
How do I buy shares of Innate Pharma?
Shares of IPHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Innate Pharma's stock price today?
One share of IPHA stock can currently be purchased for approximately $6.58.
How big of a company is Innate Pharma?
What is Innate Pharma's official website?
How can I contact Innate Pharma?
Innate Pharma's mailing address is 117 AVENUE DE LUMINY BP 30191, MARSEILLE I0, 13009. The company can be reached via phone at 33-4-30-30-30-30 or via email at [email protected]
MarketBeat Community Rating for Innate Pharma (NASDAQ IPHA)
MarketBeat's community ratings are surveys of what our community members think about Innate Pharma and other stocks. Vote "Outperform" if you believe IPHA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPHA will underperform the S&P 500 over the long term. You may vote once every thirty days.
